Medical Devices China

China Liquid Biopsy Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

China Liquid Biopsy Market Industry Trends and Forecast to 2034: Segmented by (Biomarker, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $706.8 Mn Placeholder estimate
Estimate 2025 $835.5 Mn 9.4% of the global market
Projected 2034 $3.76 Bn 350.4% Adds $2.93 Bn over 9 forecast years
CAGR 2025–2034 18.2% Faster than 90% of 173 Medical Devices markets here
Key players 6 +1
  • China is 9.39% of the global market.
  • In APAC, the largest is China (this report) at $835.5 Mn.
  • Fastest growing: India at 20% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.93 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Liquid Biopsy Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $706.8 Mn — —
2025 (base) $835.5 Mn +$128.6 Mn —
2026 (forecast) $987.5 Mn +$152.1 Mn +18.2%
2027 (forecast) $1.17 Bn +$179.7 Mn +39.7%
2028 (forecast) $1.38 Bn +$212.4 Mn +65.1%
2029 (forecast) $1.63 Bn +$251.1 Mn +95.2%
2030 (forecast) $1.93 Bn +$296.8 Mn +130.7%
2031 (forecast) $2.28 Bn +$350.8 Mn +172.7%
2032 (forecast) $2.69 Bn +$414.7 Mn +222.3%
2033 (forecast) $3.18 Bn +$490.2 Mn +281%
2034 (forecast) $3.76 Bn +$579.4 Mn +350.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Liquid Biopsy Market Analysis at a glance
Market size, 2025$835.5 Mn placeholder estimate
Forecast, 2034$3.76 Bn placeholder estimate
Growth (CAGR), 2025–203418.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsBiomarker, application and end user (see all)
Key playersGuardant Health, Inc., Roche, GRAIL, Natera, Exact Sciences Corporation and 1 more (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
Active clinical trials45 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Liquid Biopsy Market Analysis Executive Summary

Liquid biopsy finds cancer signals such as tumour DNA in a blood sample, to detect cancer, guide treatment and check for relapse.

Key segments of the liquid Biopsy market include biomarker (Circulating Tumor DNA, Circulating Tumor Cells and Exosomes) and application (Treatment Selection, Recurrence Monitoring and Early Detection).

Bar chart: China Liquid Biopsy market size, 2024–2034, placeholder estimates. $706.8 Mn in 2024, $835.5 Mn in 2025 and $3.76 Bn in 2034, 18.2% CAGR.
China Liquid Biopsy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Liquid Biopsy Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the liquid Biopsy market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the liquid Biopsy market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the liquid Biopsy market, especially in low- and middle-income countries.

Competitive Landscape for Liquid Biopsy Market in China

The liquid Biopsy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Liquid Biopsy Market in China

Liquid Biopsy in China: rules, payment and research

Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2] ClinicalTrials.gov lists 45 studies on Liquid Biopsy that are recruiting, active or about to start in China.⁠[3]

[1] National Medical Products Administration. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how liquid Biopsy products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Liquid Biopsy right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Liquid Biopsy in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Liquid Biopsy market in China?
Placeholder estimate: about $835.5 Mn in 2025, rising to about $3.76 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Liquid Biopsy market in China growing?
Placeholder estimate: about 18.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Liquid Biopsy market report cover?
The report splits the market by biomarker (Circulating Tumor DNA, Circulating Tumor Cells, Exosomes), application (Treatment Selection, Recurrence Monitoring, Early Detection) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Liquid Biopsy market?
Key players include Guardant Health, Inc., Roche, GRAIL, Natera, Exact Sciences Corporation and Illumina, Inc..
What is driving the Liquid Biopsy market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the liquid Biopsy market. Faster approvals and new combinations are improving survival.
Who regulates Liquid Biopsy in China?
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How many clinical trials on Liquid Biopsy are running in China?
45 studies are recruiting, active or about to start in China, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
How much research is published on Liquid Biopsy?
PubMed lists 10,752 papers on Liquid Biopsy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in China

See all

Related on oncology and diagnostics and lab testing

See the topic